Company: DAWN
Filing Date: 2025-01-13
Form Type: 8-K
Source: 0001193125-25-005012
Chunk: 2

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-01-13
Form: 8-K
Item: Item 9.01
Chunk 2
---
Item 9.01      Financial Statements and Exhibits.  

  (d)      Exhibits.  

  Exhibit      Description                                                                                               
                                                                                                                         
   Number                                                                                                                
     99.1      Press Release dated January 13, 2025                                                                      
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
     99.2      J. P. Morgan Healthcare Conference Presentation                                                           
     99.3      Corporate Presentation                                                                                    
      104      Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document  

Forward-Looking Statements

This Current Report on Form8-Kcontains forward-looking statements within the meaning of the U. S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the Company’s preliminary net product revenue results and cash, cash equivalents and short-term investments, as well as the timing and success of the Company’s planned nonclinical and clinical development activities, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks identified in the Company’s filings with the Securities and Exchange Commission (the “ SEC”), including its Quarterly Report on Form10-Qfor the quarter ended September 30, 2024, filed with the SEC on October 30, 2024, and the Company’s other filings with the SEC. Any of these risks and uncertainties could materially and adversely affect the Company’s results of operations, which would, in turn, have a significant and adverse impact on the Company’s stock price. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.